| First Author | Ding L | Year | 2022 |
| Journal | Front Cell Dev Biol | Volume | 10 |
| Pages | 853003 | PubMed ID | 35646902 |
| Mgi Jnum | J:324985 | Mgi Id | MGI:7282586 |
| Doi | 10.3389/fcell.2022.853003 | Citation | Ding L, et al. (2022) Nuclear GSK-3beta and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN. Front Cell Dev Biol 10:853003 |
| abstractText | Glycogen synthase kinase-3beta (GSK-3beta) is a downstream target of oncogenic KRas and can accumulate in the nucleus in pancreatic ductal adenocarcinoma (PDA). To determine the interplay between oncogenic KRas and nuclear GSK-3beta in PDA development, we generated Lox-STOP-Lox (LSL) nuclear-targeted GSK-3beta animals and crossed them with LSL-KRas(G12D) mice under the control of the Pdx1-cre transgene-referred to as KNGC. Interestingly, 4-week-old KNGC animals show a profound loss of acinar cells, the expansion of ductal cells, and the rapid development of cystic-like lesions reminiscent of intraductal papillary mucinous neoplasm (IPMN). RNA-sequencing identified the expression of several ductal cell lineage genes including AQP5. Significantly, the Aqp5(+) ductal cell pool was proliferative, phenotypically distinct from quiescent pancreatic ductal cells, and deletion of AQP5 limited expansion of the ductal pool. Aqp5 is also highly expressed in human IPMN along with GSK-3beta highlighting the putative role of Aqp5(+) ductal cells in human preneoplastic lesion development. Altogether, these data identify nGSK-3beta and KRas(G12D) as an important signaling node promoting the retention of pancreatic ductal progenitor cells, which could be used to further characterize pancreatic ductal development as well as lineage biomarkers related to IPMN and PDA. |
